GENE ONLINE|News &
Opinion
Blog

2022-06-22| Funding

Human Longevity Plans to Merge With Blank Check Company to Go Public

by Reed Slater
Share To

San Diego-based Human Longevity, a company dedicated to using individualized genetic sequencing technology to help treat age-related diseases, is planning to merge with a special-purpose acquisition company (SPAC), Freedom Acquisition Corporation 1, in a deal that would provide Human Longevity $345 million. Freedom Acquisition is a publicly owned company, so the merger would bring Human Longevity to the public market without taking the traditional route. 

 

Human Longevity’s Quest to Lengthen Life Spans

 

Human Longevity started in 2013 and has since invested $500 million in developing AI-enabled technology to analyze individualized genetic sequences to amplify patients’ life spans. 

The ambitious biotech company is one of many grouped into the anti-aging trend taking the industry by storm. Using whole-genome sequences, blood-based biomarkers, whole-body imaging, and more, it hopes to provide personalized care options and disease risk prediction models to help fight diseases associated with aging.

Going public would set Human Longevity apart from most of the rest of the anti-aging industry. Only a few other companies like AgeX Therapeutics and Unity Biotechnology have made the step to go public. 

Related Article: Massive Human CRISPR-Based Genotype-Phenotype Map Is Now Complete

 

Getting Creative to Bring a Company Public

 

With so few biotechnology companies going public in 2022 compared to 2021, companies are looking in different directions to bring extra funding amidst an unfavorable economic landscape. 

Human Longevity is taking advantage of the SPAC route using Freedom Acquisition as the publicly-owned vessel. Freedom Acquisition was listed on the New York Stock Exchange (NYSE) in April last year. Since then, the financial corporation has been looking for a company to partner with specifically to take it public.

In this potential merger, the two companies’ funds would total approximately $1 billion, providing funds for Human Longevity to continue developing its personalized healthcare projects. 

The merger would change Freedom Acquisition’s NYSE ticker mark, currently listed as FACT, to something that would better represent Human Longevity. 

The press release emphasized that the document most recently signed in the deal was a Letter of Intent, meaning that it is a non-binding agreement right now. The two companies expect to sign a finalized transaction by the third quarter of 2022 and close by the first quarter of 2023. 

The potential merger between both companies could set a precedent for future companies looking to go public in a market that makes it exceptionally difficult. The acquisition, which could provide Human Longevity a total of $1 billion, will be a huge step forward in developing individualized genetic sequencing, AI-assisted personal healthcare, and age-related chronic disease treatment.

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Lower Waist-to-Hip Ratio in Midlife Associated with Better Cognitive Function in Later Years
2025-03-14
China Blocks Illumina’s Sequencers as U.S. Tariffs Double–Trade War Fallout Intensifies
2025-03-06
Study Reveals Antidepressants May Hasten Cognitive Decline in Dementia Patients
2025-03-03
LATEST
AI-Based Model Accurately Classifies Pediatric Sarcomas Using Digital Pathology Images
2025-04-30
Taiwan’s BPIPO and DCB Join Japan’s LINK-J and FIRM for First Regenerative Medicine Investment Forum in Tokyo
2025-04-29
Study Shows ctDNA Liquid Biopsy Detects Colorectal Cancer Recurrence Earlier Than Imaging
2025-04-29
AACR Annual Meeting 2025: Cancer Research Innovations, NIH Funding Advocacy, and AI-Driven Advances
2025-04-28
Senti Biosciences to Showcase New Cell & Gene Therapy Data at AACR Annual Meeting 2025
2025-04-27
World Vaccine Congress Washington 2025 Recap: Urgent Calls for Trust, Tech, and Global Access
2025-04-25
Astellas’ Transformation Journey: From Merger to Global Player, Betting on the Edge of Innovation and Risk?
2025-04-25
EVENT
2025-04-25
AACR Annual Meeting 2025
Chicago, U.S.A
2025-05-03
29th Taiwan Joint Cancer Conference 2025
Taipei, Taiwan
2025-05-05
Swiss Biotech Day 2025
Basel, Switzerland
2025-05-13
ASGCT 28th Annual Meeting 2025
New Orleans, U.S.A.
2025-05-30
ASCO Annual Meeting 2025
Chicago, U.S.A
2025-06-11
ISSCR 2025 Annual Meeting
Hong Kong
Scroll to Top